Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 15102K100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Bank of America Corp /DE/ 13G | 6.5% |
8/11/2026
Event 6/30/2026
|
|
|
Baker Bros. Advisors LP
13G
|
10.0% |
7/16/2026
Event 7/14/2026
|
|
| Baker Bros. Advisors LP | 10.0% | ||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||
| Julian C. Baker | 10.0% | ||
| Felix J. Baker | 10.0% | ||
|
Baker Bros. Advisors LP
13D/A
Amendment 2
|
10.0% |
7/16/2026
Event 7/14/2026
|
|
| Baker Bros. Advisors LP | 10.0% | ||
| Baker Bros. Advisors (GP) LLC | 10.0% | ||
| Julian C. Baker | 10.0% | ||
| Felix J. Baker | 10.0% | ||
|
RTW Investments, LP
13G
|
6.3% |
5/15/2026
Event 3/31/2026
|
|
| RTW Investments, LP | 6.3% | ||
| Roderick Wong | 6.3% | ||
|
Baker Bros. Advisors LP
13D/A
Amendment 1
|
20.0% |
3/24/2026
Event 3/20/2026
|
|
| Baker Bros. Advisors LP | 20.0% | ||
| Baker Bros. Advisors (GP) LLC | 20.0% | ||
| Julian C. Baker | 20.0% | ||
| Felix J. Baker | 20.0% | ||
|
Growth Equity Opportunities 18 VGE, LLC
13D/A
Amendment 4
|
4.9% |
3/9/2026
Event 3/5/2026
|
|
| Growth Equity Opportunities 18 VGE, LLC | 4.9% | ||
| NEA 18 Venture Growth Equity, L.P. | 4.9% | ||
| NEA Partners 18 VGE, L.P. | 4.9% | ||
| Nea 18 Vge GP, LLC | 4.9% | ||
| Ali Behbahani | 4.9% | ||
| Carmen Chang | 4.9% | ||
| Anthony A. Florence, Jr. | 4.9% | ||
| Mohamad H. Makhzoumi | 4.9% | ||
| Edward T. Mathers | 4.9% | ||
| Scott D. Sandell | 4.9% | ||
| Paul Walker | 4.9% | ||
| Rick Yang | 4.9% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 1
|
6.8% |
2/17/2026
Event 12/31/2025
|
|
| Perceptive Advisors LLC | 6.8% | ||
| Joseph Edelman | 6.8% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 6.8% | ||
|
Avoro Capital Advisors LLC
13G
|
6.7% |
2/17/2026
Event 12/31/2025
|
|
| Avoro Capital Advisors LLC | 6.7% | ||
| Behzad Aghazadeh | 6.7% | ||
|
Soleus Private Equity Fund II, L.P.
13G/A
Amendment 5
|
3.9% |
2/12/2026
Event 12/31/2025
|
|
| Soleus Private Equity Fund II, L.P. | 0.3% | ||
| Soleus Private Equity GP II, LLC | 0.3% | ||
| Soleus PE GP II, LLC | 0.3% | ||
| Soleus Capital Master Fund, L.P. | 3.6% | ||
| Soleus Capital, LLC | 3.6% | ||
| Soleus Capital Group, LLC | 3.6% | ||
| Soleus Capital Management, L.P. | 3.9% | ||
| Soleus GP, LLC | 3.9% | ||
| Guy Levy | 3.9% | ||
|
Growth Equity Opportunities 18 VGE, LLC
13D/A
Amendment 3
|
6.3% |
1/16/2026
Event 1/14/2026
|
|
| Growth Equity Opportunities 18 VGE, LLC | 6.3% | ||
| NEA 18 Venture Growth Equity, L.P. | 6.3% | ||
| NEA Partners 18 VGE, L.P. | 6.3% | ||
| Nea 18 Vge GP, LLC | 6.3% | ||
| Ali Behbahani | 6.3% | ||
| Carmen Chang | 6.3% | ||
| Anthony A. Florence, Jr. | 6.3% | ||
| Mohamad H. Makhzoumi | 6.3% | ||
| Edward T. Mathers | 6.3% | ||
| Scott D. Sandell | 6.3% | ||
| Paul Walker | 6.3% | ||
| Rick Yang | 6.3% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 1
|
1.6% |
11/14/2025
Event 9/30/2025
|
|
| Biotechnology Value Fund L P | 0.8% | ||
| BVF I GP LLC | 0.8% | ||
| Biotechnology Value Fund II LP | 0.6% | ||
| BVF II GP LLC | 0.6% | ||
| Biotechnology Value Trading Fund OS LP | 0.1% | ||
| BVF Partners OS Ltd. | 0.1% | ||
| BVF GP Holdings LLC | 1.4% | ||
| BVF Partners L P/IL | 1.6% | ||
| BVF Inc/IL | 1.6% | ||
| Lampert Mark N | 1.6% | ||
| Brian F. Sullivan 13G/A Amendment 6 | 9.1% |
11/13/2025
Event 9/30/2025
|
|
| Lance G. Laing 13G/A Amendment 6 | 3.6% |
11/13/2025
Event 9/30/2025
|
|
|
Growth Equity Opportunities 18 VGE, LLC
13D/A
Amendment 2
|
8.1% |
8/18/2025
Event 8/14/2025
|
|
| Growth Equity Opportunities 18 VGE, LLC | 8.1% | ||
| NEA 18 Venture Growth Equity, L.P. | 8.1% | ||
| NEA Partners 18 VGE, L.P. | 8.1% | ||
| Nea 18 Vge GP, LLC | 8.1% | ||
| Ali Behbahani | 8.1% | ||
| Carmen Chang | 8.1% | ||
| Anthony A. Florence, Jr. | 8.1% | ||
| Liza Landsman | 0% | ||
| Mohamad H. Makhzoumi | 8.1% | ||
| Edward T. Mathers | 8.1% | ||
| Scott D. Sandell | 8.1% | ||
| Peter W. Sonsini | 0% | ||
| Paul Walker | 8.1% | ||
| Rick Yang | 8.1% | ||
|
Perceptive Advisors LLC
13G
|
6.6% |
8/4/2025
Event 7/30/2025
|
|
| Perceptive Advisors LLC | 6.6% | ||
| Joseph Edelman | 6.6% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 6.6% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 3
|
4.3% |
8/4/2025
Event 6/30/2025
|
|
| Perceptive Advisors LLC | 4.3% | ||
| Joseph Edelman | 4.3% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 4.3% | ||
|
Baker Bros. Advisors LP
13D
|
18.9% |
8/1/2025
Event 8/1/2025
|
|
| Baker Bros. Advisors LP | 18.9% | ||
| Baker Bros. Advisors (GP) LLC | 18.9% | ||
| Julian C. Baker | 18.9% | ||
| Felix J. Baker | 18.9% | ||
|
Baker Bros. Advisors LP
13G/A
Amendment 2
|
11.3% |
4/7/2025
Event 3/31/2025
|
|
| Baker Bros. Advisors LP | 11.3% | ||
| Baker Bros. Advisors (GP) LLC | 11.3% | ||
| Julian C. Baker | 11.3% | ||
| Felix J. Baker | 11.3% | ||
|
Commodore Capital LP
13G/A
Amendment 5
|
2.9% |
2/14/2025
Event 12/31/2024
|
|
| Commodore Capital LP | 2.9% | ||
| Commodore Capital Master LP | 2.9% | ||
|
Baker Bros. Advisors LP
13G/A
Amendment 1
|
7.2% |
2/14/2025
Event 12/31/2024
|
|
| Baker Bros. Advisors LP | 7.2% | ||
| Baker Bros. Advisors (GP) LLC | 7.2% | ||
| Julian C. Baker | 7.2% | ||
| Felix J. Baker | 7.2% | ||
|
Perceptive Advisors LLC
13G/A
Amendment 2
|
6.4% |
2/14/2025
Event 12/31/2024
|
|
| Perceptive Advisors LLC | 6.4% | ||
| Joseph Edelman | 6.4% | ||
| Perceptive Life Sciences Master Fund, Ltd. | 6.4% | ||
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 4
|
9.9% |
2/11/2025
Event 12/31/2024
|
|
| Soleus Private Equity Fund II, L.P. | 4.6% | ||
| Soleus Private Equity GP II, LLC | 4.6% | ||
| Soleus PE GP II, LLC | 4.6% | ||
| Soleus Capital Master Fund, L.P. | 9.9% | ||
| Soleus Capital, LLC | 9.9% | ||
| Soleus Capital Group, LLC | 9.9% | ||
| Soleus Capital Management, L.P. | 9.9% | ||
| Soleus GP LLC | 9.9% | ||
| Guy Levy | 9.9% | ||
| BlackRock, Inc. 13G | 5.9% |
2/4/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 8.06 k | $640 k |
| 2026 Q2 | 289 | 58.9 M | $5.98 B |
| 2026 Q1 | 298 | 49.1 M | $5.58 B |
| 2025 Q4 | 254 | 48.1 M | $4.81 B |
| 2025 Q3 | 191 | 39.2 M | $1.93 B |
| 2025 Q2 | 100 | 31.7 M | $423 M |
| 2025 Q1 | 100 | 30.9 M | $312 M |
| 2024 Q4 | 109 | 30.4 M | $403 M |
| 2024 Q3 | 111 | 30.0 M | $450 M |
| 2024 Q2 | 98 | 32.2 M | $530 M |
| 2024 Q1 | 86 | 26.9 M | $582 M |
| 2023 Q4 | 64 | 18.2 M | $265 M |
| 2023 Q3 | 60 | 15.4 M | $161 M |
| 2023 Q2 | 59 | 14.0 M | $153 M |
| 2023 Q1 | 45 | 12.1 M | $124 M |
| 2022 Q4 | 43 | 11.2 M | $157 M |
| 2022 Q3 | 31 | 4.80 M | $48.2 M |
| 2022 Q2 | 42 | 4.67 M | $42.5 M |
| 2022 Q1 | 54 | 5.28 M | $47.9 M |
| 2021 Q4 | 56 | 5.42 M | $71.5 M |
| 2021 Q3 | 63 | 5.69 M | $102 M |
| 2021 Q2 | 67 | 6.48 M | $156 M |
| 2021 Q1 | 42 | 3.27 M | $46.9 M |
| 2020 Q4 | 30 | 1.94 M | $17.7 M |
| 2020 Q3 | 31 | 1.91 M | $11.1 M |
| 2020 Q2 | 37 | 2.08 M | $14.4 M |
| 2020 Q1 | 44 | 2.26 M | $14.7 M |
| 2019 Q4 | 48 | 2.28 M | $24.3 M |
| 2019 Q3 | 48 | 2.27 M | $38.6 M |
| 2019 Q2 | 47 | 2.30 M | $57.4 M |
| 2019 Q1 | 46 | 2.25 M | $49.3 M |
| 2018 Q4 | 46 | 2.29 M | $54.8 M |
| 2018 Q3 | 49 | 1.58 M | $45.5 M |
| 2018 Q2 | 48 | 1.46 M | $36.1 M |
| 2018 Q1 | 39 | 1.34 M | $22.0 M |
| 2017 Q4 | 38 | 1.39 M | $26.3 M |
| 2017 Q3 | 17 | 1.34 M | $16.4 M |